AMLX logo

Amylyx Pharmaceuticals (AMLX)

Profile

Full Name

Amylyx Pharmaceuticals, Inc.

Ticker Symbol

AMLX

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

January 7, 2022

Indexes

Not included

Website

http://amylyx.com

Employees

123

Key Details

Price

$3.37

Market Cap

$298.15M(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$87.37M(-77.06% YoY)

Annual EPS

-$4.43(-732.86% YoY)

PE Ratio

-

Next earnings date

May 9, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$3.37
AMLX price is $3.37

Price All-time High

$41.11
AMLX price is currently -91.81% below its historical high of $41.11

Price Today Change

-8.56%
AMLX price is down -8.56% today

Price YTD Change

-9.05%
AMLX price is down -9.05% since January 1st

Price 1-year Change

+29.92%
AMLX price is up +29.92% year-on-year

Price 3-year Change

-75.79%
AMLX price is down -75.79% over the past 3 years

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market Cap

$298.15M
AMLX market capitalization is $298.15 million

Market Cap 3-year Change

-62.93%
AMLX market capitalization is down -62.93% over the past 3 years

Market Cap All-time High

$2.73B
AMLX market capitalization is currently -89.10% below its historical high of $2.73 billion

Market Cap Sector Rank

63.49%
AMLX market capitalization is higher than 63.49% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+30.34%
AMLX shares outstanding is up +30.34% year-on-year

Shares Outstanding 3-Year Change

+53.12%
AMLX shares outstanding is up +53.12% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

1.65
AMLX beta is 1.65

200-day SMA

$3.43
AMLX price is currently -1.78% below its 200-day simple moving average

50-day SMA

$3.55
AMLX price is currently -5.13% below its 50-day simple moving average

RSI

47.56
AMLX 14-day relative strength index is 47.56

Volume

1.32
AMLX 30-day relative volume is 1.32

ATR

$0.30
AMLX average true range is $0.30

10-day Historical Volatility

93.89%
AMLX 10-day historical volatility is 93.89%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$87.37M
AMLX annual revenue is $87.37 million

Revenue Analysts Estimate

-
AMLX annual revenue consensus analysts' forecast is unknown

Revenue 1-year Change

-77.06%
AMLX annual revenue is down -77.06% year-on-year

Revenue Sector Rank

56.76%
AMLX annual revenue is higher than 56.76% of companies in Healthcare sector

EPS

EPS

-$4.43
AMLX annual earnings per share is -$4.43

EPS Analysts Estimate

-$2.26
AMLX annual earnings per share is currently +96.02% higher than the consensus analysts' forecast

EPS 1-year Change

-732.86%
AMLX annual earnings per share is down -732.86% year-on-year

EPS Sector Rank

21%
AMLX annual earnings per share is higher than 21% of companies in Healthcare sector

Profit

Gross Profit

-$37.26M
AMLX annual gross profit is -$37.26 million

Gross Margin

-42.65%
AMLX annual gross profit margin is -42.65%

Operating Profit

-$291.88M
AMLX annual operating income is -$291.88 million

Operating Margin

-334.07%
AMLX annual operating profit margin is -334.07%

Net Income

-$301.74M
AMLX annual net profit is -$301.74 million

Net Margin

-345.36%
AMLX annual net profit margin is -345.36%

Expenses

Total Expenses

$379.25M
AMLX annual total expenses is $379.25 million

Operating Expenses

$254.62M
AMLX annual total operating expenses is $254.62 million

Cost Of Goods Sold

$124.63M
AMLX annual cost of goods sold is $124.63 million

Selling, General & Administrative Expenses

$114.33M
AMLX annual SGA is $114.33 million

Depreciation And Amortization

$904.00K
AMLX annual depreciation & amortization is $904.00 thousand

Interest Expense

-
AMLX annual interest expense value is unknown

Income Tax

-$393.00K
AMLX annual income tax is -$393.00 thousand

EBIT & EBITDA

EBIT

-$291.88M
AMLX annual earnings before interest & taxes is -$291.88 million

EBITDA

-$290.98M
AMLX annual EBITDA is -$290.98 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total Assets

$193.63M
AMLX annual total assets is $193.63 million

Non Current Assets

$4.20M
AMLX annual long term assets is $4.20 million

Current Assets

$189.43M
AMLX annual total current assets is $189.43 million

Cash And Cash Equivalents

$77.39M
AMLX annual cash & cash equivalents is $77.39 million

Accounts Receivable

$447.00K
AMLX annual accounts receivable is $447.00 thousand

Inventory

$0.00
AMLX annual inventory is $0.00

Liabilities

Total Liabilities

$28.87M
AMLX annual total liabilities is $28.87 million

Long Term Liabilities

$463.00K
AMLX annual total long term liabilities is $463.00 thousand

Current Liabilities

$28.41M
AMLX annual total current liabilities is $28.41 million

Accounts Payable

$2.94M
AMLX annual accounts payable is $2.94 million

Debt

Total Debt

$1.98M
AMLX annual total debt is $1.98 million

Total Debt 1-year Change

-53.25%
AMLX annual total debt is down -53.25% year-on-year

Long Term Debt

$463.00K
AMLX annual long term debt is $463.00 thousand

Short Term Debt

$1.52M
AMLX annual short term debt is $1.52 million

Equity & Capital

Shareholders Equity

$164.76M
AMLX annual stockholders equity is $164.76 million

Book Value

$164.76M
AMLX annual book value is $164.76 million

Retained Earnings

-$606.69M
AMLX annual retained earnings is -$606.69 million

Working Capital

$161.03M
AMLX annual working capital is $161.03 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash From Operations

-$167.65M
AMLX annual cash flow from operations is -$167.65 million

Cash From Operations 1-year Change

-1506.55%
AMLX annual cash flow from operations is down -1506.55% year-on-year

Cash From Investing

$75.65M
AMLX annual cash flow from investing activities is $75.65 million

Cash From Investing 1-year Change

-17.81%
AMLX annual cash flow from investing activities is down -17.81% year-on-year

Cash From Financing

$348.00K
AMLX annual cash flow from financing activities is $348.00 thousand

Cash From Financing 1-year Change

-90.18%
AMLX annual cash flow from financing activities is down -90.18% year-on-year

CAPEX

CAPEX

$157.00K
AMLX annual capital expenditures is $157.00 thousand

CAPEX 1-year Change

-87.35%
AMLX annual capital expenditures is down -87.35% year-on-year

Free Cash Flow

Free Cash Flow

-$167.80M
AMLX annual free cash flow is -$167.80 million

Free Cash Flow 1-year Change

-1671.49%
AMLX annual free cash flow is down -1671.49% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross Margin

-42.65%
AMLX annual gross profit margin is -42.65%

Operating Margin

-334.07%
AMLX annual operating profit margin is -334.07%

Net Margin

-345.36%
AMLX annual net profit margin is -345.36%

ROA & ROE

ROA

-84.87%
AMLX annual return on assets is -84.87%

ROE

-100.88%
AMLX annual return on equity is -100.88%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
AMLX price to earnings ratio value is unknown

PE Ratio Sector Rank

-
AMLX price to earnings ratio is unknown

PB Ratio

PB Ratio

1.81
AMLX price to book ratio is 1.81

PB Ratio Sector Rank

61.74%
AMLX price to book ratio is higher than 61.74% of companies in Healthcare sector

PS Ratio

PS Ratio

3.41
AMLX price to sales ratio is 3.41

PS Ratio Sector Rank

57.87%
AMLX price to sales ratio is higher than 57.87% of companies in Healthcare sector

Enterprise value

Enterprise Value

$222.74M
AMLX enterprise value is $222.74 million

Enterprise Value Sector Rank

60.89%
AMLX enterprise value is higher than 60.89% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-0.77
AMLX EV/EBITDA is -0.77

EV/EBITDA Sector Rank

45.15%
AMLX EV/EBITDA is higher than 45.15% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current Ratio

6.67
AMLX annual current ratio is 6.67

Quick Ratio

6.67
AMLX annual quick ratio is 6.67

Leverage

Debt To Equity

0.00
AMLX annual debt to equity ratio is 0.00

Interest Coverage Ratio

-
AMLX annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

-
AMLX piotroski f-score value is unknown

Altman Z-Score

-1.72
AMLX altman z-score is -1.72

Analyst ratings

Recent major analysts updates

Mar 5, 25 HC Wainwright & Co.
Buy
Dec 5, 24 HC Wainwright & Co.
Buy
Nov 18, 24 Baird
Outperform
Nov 8, 24 HC Wainwright & Co.
Buy
Oct 18, 24 HC Wainwright & Co.
Buy
Jul 12, 24 Goldman Sachs
Neutral
Jul 10, 24 HC Wainwright & Co.
Buy
Jun 24, 24 HC Wainwright & Co.
Buy
May 14, 24 Mizuho
Neutral
May 10, 24 HC Wainwright & Co.
Buy

Institutional Ownership

Similar stocks

HRTX logo
Heron Therapeutics (HRTX)
Tectonic Therapeutic (TECX)
SMLR logo
Semler Scientific (SMLR)
RGNX logo
REGENXBIO (RGNX)
Claritev (CTEV)
MPLN logo
MultiPlan (MPLN)
CELC logo
Celcuity (CELC)
TCMD logo
Tactile Systems Technology (TCMD)
DNA logo
Ginkgo Bioworks Holdings (DNA)
  • What is the ticker symbol for Amylyx Pharmaceuticals?
  • Does Amylyx Pharmaceuticals pay dividends?
  • What sector is Amylyx Pharmaceuticals in?
  • What industry is Amylyx Pharmaceuticals in?
  • What country is Amylyx Pharmaceuticals based in?
  • When did Amylyx Pharmaceuticals go public?
  • Is Amylyx Pharmaceuticals in the S&P 500?
  • Is Amylyx Pharmaceuticals in the NASDAQ 100?
  • Is Amylyx Pharmaceuticals in the Dow Jones?
  • When was Amylyx Pharmaceuticals's last earnings report?
  • When does Amylyx Pharmaceuticals report earnings?
  • Should I buy Amylyx Pharmaceuticals stock now?

What is the ticker symbol for Amylyx Pharmaceuticals?

The ticker symbol for Amylyx Pharmaceuticals is NASDAQ:AMLX

Does Amylyx Pharmaceuticals pay dividends?

No, Amylyx Pharmaceuticals does not pay dividends

What sector is Amylyx Pharmaceuticals in?

Amylyx Pharmaceuticals is in the Healthcare sector

What industry is Amylyx Pharmaceuticals in?

Amylyx Pharmaceuticals is in the Biotechnology industry

What country is Amylyx Pharmaceuticals based in?

Amylyx Pharmaceuticals is headquartered in United States

When did Amylyx Pharmaceuticals go public?

Amylyx Pharmaceuticals's initial public offering (IPO) was on January 7, 2022

Is Amylyx Pharmaceuticals in the S&P 500?

No, Amylyx Pharmaceuticals is not included in the S&P 500 index

Is Amylyx Pharmaceuticals in the NASDAQ 100?

No, Amylyx Pharmaceuticals is not included in the NASDAQ 100 index

Is Amylyx Pharmaceuticals in the Dow Jones?

No, Amylyx Pharmaceuticals is not included in the Dow Jones index

When was Amylyx Pharmaceuticals's last earnings report?

Amylyx Pharmaceuticals's most recent earnings report was on Mar 4, 2025

When does Amylyx Pharmaceuticals report earnings?

The next expected earnings date for Amylyx Pharmaceuticals is May 9, 2025

Should I buy Amylyx Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page